8/09/2012 @ 6:47下午 |372 viewsTwo new papers provide further evidence that statin usage is associated with an increased risk of diabetes, but both studies also find that the benefits of statins still outweigh the risks.In the first report, published in the Lancet, Paul Ridker and colleagues analyze data from the JUPITER trial, which compared rosuvastatin to placebo in a primary prevention population.Among the 17,603 patients randomized in the trial, 11,508 had at least one major risk factor for developing diabetes. In this group, the primary endpoint (MI, stroke, hospitalization for unstable angina, revascularization, or CV death) was reduced by 39% in the statin group (hazard ratio 0·61, CI 0.47–0.79, p=0·0001). The authors calculated that in the statin group 134 vascular events or deaths were avoidedfor every 54 new cases of diabetes. For the 6,095 patients without a major risk factor for diabetes, the primary endpoint was reduced by 52%(HR 0·48, CI 0.33–0.68, p=0·0001). No increase in diabetes was observed. In this group, 86 vascular events or deaths were avoided. During the JUPITER trial 486 subjects developed diabetes (270 in the rosuvastatin group and 216 in the placebo group). The risk reduction in this group was consistent with the overall reduction observed in the trial."Our results show that in participants with and without diabetes risk, the absolute benefits of statin therapy are greater than the hazards of developing diabetes," said Paul Ridker, in a press release issued by the Lancet. "We believe that most physicians and patients would regard heart attack, stroke and death to be more severe outcomes than the onset of diabetes, and so we hope that these results ease concern about the risks associated with statin therapy when these drugs are appropriately prescribed – in conjunction with improved diet, exercise and smoking cessation – to reduce patients' risk of cardiovascular disease."The findings from JUPITER were echoed in a large observational study from Taiwan published in the Journal of the American College of Cardiology that compared 8,412 people receiving statins with 33,648 matched controls. The Taiwan investigators found that although, over a median of 7.2 years, the rate of diabetes was significantly higher among statin users(2.4% vs. 2.1%, p < 0.001), statins were associated with a significant reduction in cardiovascular events (HR 0.91, CI 0.84 to 0.99, p = 0.031). Here is the press release from the Lancet:
Cardiovascular benefits of taking statins outweigh diabetes risk The benefits of taking statins to reduce the risk of cardiovascular disease outweigh the increased risk of developing diabetes experienced by some patients who take these cholesterol-lowering drugs, according to an Article published Online First in The Lancet.A team of scientists led by Professor Paul Ridker, based at Brigham and Women's Hospital, Boston, USA, analysed data gathered during JUPITER*, the first controlled study to report that taking statins results in an increased risk of developing diabetes.This finding, subsequently confirmed by several other studies, led to the US Food and Drug Administration (FDA) enforcing a compulsory warning on statin labels, advising users of the increased risk of diabetes. Professor Ridker and colleagues analysed the JUPITER results to determine whether or not the risk of developing diabetes was outweighed by the benefits to cardiovascular health conferred on patients who took statins over the five year trial period. They found marked differences in the likelihood of developing diabetes, depending on whether or not the patient was already at risk of developing diabetes when the trial began. Patients who had at least one risk factor for diabetes were 28% more likely to develop diabetes when using statins, compared to patients in the control group. However, there was no discernible increase in the risk of developing diabetes for patients who did not have any risk factors for diabetes. Although the use of statins clearly increased the likelihood of developing diabetes in patients already at risk of the disease, these patients were still 39% less likely to develop cardiovascular illness while using statins, and 17% less likely to die over the trial period. Patients who were not already at risk of developing diabetes experienced a 52% reduction in cardiovascular illness when taking statins, and had no increase in diabetes risk. According to Professor Ridker, "Our results show that in participants with and without diabetes risk, the absolute benefits of statin therapy are greater than the hazards of developing diabetes .We believe that most physicians and patients would regard heart attack, stroke and death to be more severe outcomes than the onset of diabetes, and so we hope that these results ease concern about the risks associated with statin therapy when these drugs are appropriately prescribed – in conjunction with improved diet, exercise and smoking cessation – to reduce patients' risk of cardiovascular disease." Notes to Editors:* JUPITER ('Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin') was a large-scale study, involving almost 18 000 patients, designed to determine whether taking a statin called rosuvastatin would decrease the rate of cardiovascular illness in patients who had never previously suffered from cardiovascular disease.
